Tusamitamab Ravtansine ADC for NSCLC Patient Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies for disease progression after first-line treatment are limited by serious hematological and toxicities, and existing cytotoxic agents like docetaxel offer limited options with significant side effects.
Innovation Solution
The use of an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody conjugated to a cytotoxic maytansinoid agent, specifically tusamitamab ravtansine, which is administered based on circulating carcinoembryonic antigen (CEA) levels ≥5 ng/mL to target cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cytotoxic agents like docetaxel are used for cancer treatment after first-line therapy, then some anti-tumor effect is achieved, but serious hematological and other toxicities occur
Solution Approach 1:
The patent uses an antibody-drug conjugate (ADC) as an intermediary system that consists of three components: an anti-CEACAM5 antibody that targets tumor cells, a linker that connects the antibody to the cytotoxic agent, and a maytansinoid cytotoxic agent that kills the tumor cells. This intermediary structure allows the cytotoxic agent to be delivered specifically to tumor cells rather than systemically, thereby maintaining anti-tumor efficacy while reducing hematological and other toxicities associated with traditional chemotherapy agents like docetaxel
Solution Approach 2:
The ADC utilizes the tumor cell's own CEACAM5 surface antigen expression as a self-identifying marker. The anti-CEACAM5 antibody in the ADC specifically binds to CEACAM5-expressing tumor cells, allowing the therapeutic system to automatically target and destroy tumor cells that express the antigen while sparing normal cells. This self-service mechanism enables selective tumor cell killing without requiring external targeting systems
2Ease of operation
If single cytotoxic agents like docetaxel, pemetrexed, or gemcitabine are used, then treatment simplicity is maintained, but therapeutic options are very limited
Solution Approach 1:
The patent merges multiple therapeutic functions into a single ADC molecule: the anti-CEACAM5 antibody provides tumor targeting, the linker ensures stable circulation and controlled drug release, and the maytansinoid agent delivers potent cytotoxic activity. This merged structure creates a unified therapeutic agent that combines specificity, stability, and efficacy in one platform, expanding therapeutic options beyond single-agent chemotherapy while maintaining ease of administration
Solution Approach 2:
The ADC platform demonstrates universality by using the same anti-CEACAM5 antibody framework that can be applied across multiple cancer types that express CEACAM5, including colorectal cancer, gastric cancer, lung cancer, and others. This multi-functional platform can address various malignancies with a single therapeutic approach, significantly expanding the versatility of treatment options available to patients with different cancer types
Data Source
AI summary
Provided are methods for identifying and treating patients with cancer, where the cancer expresses CEACAM5. The methods include measuring circulating CEA to identify patients likely to benefit from treatment with an agent specific for CEACAM5. Such patients can have high circulating CEA and only low or medium expression of CEACAM5 on tumor cells as measured by immunohistochemistry (IHC). The agent specific for CEACAM5 can be tusamitamab ravtansine. Such agent can be used in combination with one or more additional agents to treat the cancer. In certain embodiments the cancer is non-squamous non-small cell lung cancer (NSQ NSCLC).